Visual outcome, local tumour control, and eye preservation after 106Ru/Rh brachytherapy for choroidal melanoma.
To study the visual outcome, local tumour control, and eye preservation 5 years after ruthenium/rhodium 106 brachytherapy for choroidal melanoma. The study included 55 consecutive patients treated by 106Ru/Rh brachytherapy for a choroidal melanoma during the period 1988-2000 and followed through 2004. The 5-year probability for not losing at least 5 Snellen lines was 59% (n = 45), for retaining a visual acuity of 0.33 or better was 28% (n = 34), and for retaining better than 0.1 was 40% (n = 45). The 5-year probability for no local recurrence was 73% and for eye preservation 72% (n = 55). 106Ru/Rh brachytherapy for choroidal melanoma resulted in a clinically significant vision loss, no local recurrence, and eye preservation in most patients after 5 years. 106Ru/Rh brachytherapy can be regarded as a good treatment option for small and medium-sized tumours but not for large tumours.
Isager
Peter
P
Department of Ophthalmology, Arhus University Hospital, Denmark. isager@dadlnet.dk
Ehlers
Niels
N
Urbak
Steen F
SF
Overgaard
Jens
J
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001918:Brachytherapy / Q000706:statistics & numerical data; D002830:Choroid Neoplasms / Q000532:radiotherapy*; D005123:Eye / Q000166:cytology*; D015353:Eye Enucleation / Q000706:statistics & numerical data; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008545:Melanoma / Q000150:complications / Q000532:radiotherapy*; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D012238:Rhodium / Q000627:therapeutic use; D012428:Ruthenium / Q000627:therapeutic use; D016896:Treatment Outcome; D014792:Visual Acuity / Q000528:radiation effects*
D012428:Ruthenium; D012238:Rhodium